RBC Capital Reiterates Outperform on Globus Medical, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh has reiterated an Outperform rating on Globus Medical (NYSE:GMED) and maintained a price target of $70.
January 11, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst reaffirms Outperform rating on Globus Medical with a $70 price target, indicating a positive outlook on the stock.
The reiteration of an Outperform rating by a prominent analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price. The maintained price target of $70 suggests that the analyst believes the stock has room to grow from its current level.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100